

Cristina Gervasoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4752180/publications.pdf>

Version: 2024-02-01

119
papers

2,856
citations

361045

20
h-index

189595

50
g-index

120
all docs

120
docs citations

120
times ranked

5147
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 889-890.	2.9	1,057
2	Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. <i>Aids</i> , 1999, 13, 465-471.	1.0	279
3	Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. <i>Clinical Infectious Diseases</i> , 2020, 71, 2276-2278.	2.9	182
4	Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. <i>HIV Medicine</i> , 2021, 22, 372-378.	1.0	123
5	Thrombotic Microangiopathy in Patients with Acquired Immunodeficiency Syndrome Before and During the Era of Introduction of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2002, 35, 1534-1540.	2.9	77
6	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 460-464.	1.3	55
7	Darunavir does not prevent SARS-CoV-2 infection in HIV patients. <i>Pharmacological Research</i> , 2020, 157, 104826.	3.1	49
8	Therapeutic drug management of linezolid: a missed opportunity for clinicians?. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 728-731.	1.1	48
9	Immunoendocrinologic Abnormalities in Human Immunodeficiency Virus Infection. <i>Annals of the New York Academy of Sciences</i> , 2000, 917, 956-961.	1.8	39
10	Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. <i>Clinical Rheumatology</i> , 2013, 32, 1399-1405.	1.0	38
11	Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events. <i>PLoS ONE</i> , 2013, 8, e80242.	1.1	34
12	Comparison of the <i>In Vivo</i> Pharmacokinetics and <i>In Vitro</i> Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6132-6136.	1.4	30
13	Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 319-327.	0.6	30
14	Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2704-2706.	1.3	30
15	Does lopinavir really inhibit SARS-CoV-2?. <i>Pharmacological Research</i> , 2020, 158, 104898.	3.1	29
16	Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?. <i>PLoS ONE</i> , 2015, 10, e0123670.	1.1	26
17	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 86-92.	0.9	25
18	Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. <i>Aids</i> , 2004, 18, 574-576.	1.0	24

#	ARTICLE	IF	CITATIONS
19	Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 193-201.	0.9	24
20	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 1421-1427.	2.5	24
21	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. <i>Drugs and Aging</i> , 2020, 37, 925-933.	1.3	23
22	Abacavir Hypersensitivity Reaction after Switching from the Twice-Daily to the Once-Daily Formulation. <i>AIDS Patient Care and STDs</i> , 2007, 21, 1-3.	1.1	20
23	Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. <i>Pharmacological Research</i> , 2012, 65, 198-203.	3.1	19
24	How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, e24-e26.	0.9	18
25	Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1842-1844.	1.3	18
26	Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1611-1613.	0.8	17
27	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2236-2242.	1.3	16
28	Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic. <i>AIDS Reviews</i> , 2019, 21, 40-49.	0.5	15
29	Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 440-445.	1.0	14
30	Dolutegravir Plasma Concentrations According to Companion Antiretroviral Drug: Unwanted Drug Interaction or Desirable Boosting Effect?. <i>Antiviral Therapy</i> , 2017, 22, 353-356.	0.6	14
31	The management of anti-infective agents in intensive care units: the potential role of a "fast" pharmacology. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 355-366.	1.3	14
32	Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2918-2920.	1.3	13
33	Maintenance of Breast Size Reduction After Mastoplasty and Switch to a Protease Inhibitor-Sparing Regimen in an HIV-Positive Woman with Highly Active Antiretroviral Therapy-Associated Massive Breast Enlargement. <i>AIDS Patient Care and STDs</i> , 2002, 16, 307-311.	1.1	12
34	Fat Redistribution in HIV-Infected Patients: A New Hormonal-Immune Disorder?. <i>Annals of the New York Academy of Sciences</i> , 2006, 917, 951-955.	1.8	12
35	Is it time to revise linezolid dose in elderly patients?. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1335-1336.	0.8	12
36	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 103-109.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?. <i>Clinical Pharmacokinetics</i> , 2021, 60, 603-609.	1.6	12
38	Abacavir-induced liver toxicity. <i>Brazilian Journal of Infectious Diseases</i> , 2016, 20, 502-504.	0.3	11
39	Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. <i>Journal of Clinical Virology</i> , 2016, 74, 75-77.	1.6	11
40	Intolerance of dolutegravir-containing combination antiretroviral therapy. <i>Aids</i> , 2017, 31, 867-868.	1.0	11
41	Prolonged inductive effect of rifampicin on linezolid exposure. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 643-644.	0.8	10
42	Viro-Immunological Response of Drug-Naive HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	0.6	10
43	Dolutegravir and metformin. <i>Aids</i> , 2018, 32, 532-533.	1.0	10
44	Drug-induced liver steatosis in patients with HIV infection. <i>Pharmacological Research</i> , 2019, 145, 104267.	3.1	10
45	Body Habitus Alterations in HIV-Infected Women Treated with Combined Antiretroviral Therapy. <i>AIDS Patient Care and STDs</i> , 2000, 14, 595-601.	1.1	9
46	Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count. <i>Journal of Medical Virology</i> , 2014, 86, 97-101.	2.5	9
47	Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 64-74.	1.0	9
48	Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2003, 8, 347-354.	0.6	9
49	Orlistat: weight lost at cost of HIV rebound. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1739-1741.	1.3	8
50	Renal function in <sc>HIV</sc>/<sc>HBV</sc> coâ€infecte and <sc>HBV</sc> monoâ€infecte patients on a longâ€term treatment with tenofovir in real life setting. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 191-196.	0.9	8
51	Loss of Control of HIV Viremia With OTC Weightâ€Loss Drugs: A Call for Caution?. <i>Obesity</i> , 2018, 26, 1251-1252.	1.5	8
52	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 651-657.	1.3	8
53	Drugâ€Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021, 38, 341-346.	1.3	8
54	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. <i>Pharmacogenomics Journal</i> , 2021, 21, 586-593.	0.9	8

#	ARTICLE	IF	CITATIONS
55	HIV education and counselling using Facebook: a possible new approach. <i>Journal of Telemedicine and Telecare</i> , 2012, 18, 239-240.	1.4	7
56	Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfecting patient on long-term maintenance methadone therapy. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1027-1028.	0.8	7
57	Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfecting Patients: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 285-286.	2.9	7
58	When food can make the difference: The case of elvitegravir-based co-formulation. <i>International Journal of Pharmaceutics</i> , 2016, 512, 301-304.	2.6	7
59	How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2271-2273.	1.3	7
60	Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 330-334.	1.0	7
61	Comparability of Echographic and Tomographic Assessments of Body Fat Changes Related to the HIV Associated Adipose Redistribution Syndrome (HARS) in Antiretroviral Treated Patients. <i>Ultrasound in Medicine and Biology</i> , 2008, 34, 1043-1048.	0.7	6
62	Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1206-1207.	1.3	6
63	Use of Direct Oral Anticoagulants in People Living with HIV: A Single-Center Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 999-1001.	1.5	6
64	Is Chewed Raltegravir an Option to Care for HIV-Infected Patients With Active Tuberculosis?. <i>Clinical Infectious Diseases</i> , 2013, 57, 480-481.	2.9	5
65	Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2014, 28, 285-287.	1.0	5
66	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfecting patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 545-549.	1.1	5
67	Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 383-385.	0.8	5
68	Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1341-1345.	1.3	5
69	Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 559-572.	0.6	5
70	The Relevance of Drug-drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration. <i>Antiviral Therapy</i> , 2018, 23, 467-469.	0.6	5
71	Recurring infections due to community-acquired Pantón-Valentine leukocidin-producing <i>Staphylococcus aureus</i> in the Milan area. <i>Journal of Infection and Public Health</i> , 2018, 11, 255-259.	1.9	5
72	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 59-65.	1.0	5

#	ARTICLE	IF	CITATIONS
73	COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. <i>International Journal of Cardiology</i> , 2020, 318, 160-164.	0.8	5
74	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 841-844.	0.6	5
75	Tubercular Gluteus Abscesses: A Return to The Early 20th Century or a Consequence of New, Unprecedented Behaviors?. <i>Clinical Infectious Diseases</i> , 2011, 52, 1082-1083.	2.9	4
76	Pharmacokinetic concerns related to the AIDS Clinical Trial Group (ACTG) A5262 trial. <i>Aids</i> , 2012, 26, 398-400.	1.0	4
77	ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 743-745.	0.8	4
78	Seizures in Patients with Chronic Hepatitis C Treated with NS3/4A Protease Inhibitors: Does Pharmacological Interaction Play a Role?. <i>Pharmacology</i> , 2013, 92, 235-237.	0.9	4
79	Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. <i>Antiviral Therapy</i> , 2014, 20, 449-451.	0.6	4
80	Elvitegravir/Cobicistat-Associated Toxic Optical Neuropathy in an HIV-Infected Patient: A Call for Caution?. <i>Antiviral Therapy</i> , 2017, 22, 453-455.	0.6	4
81	Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1177-1178.	0.8	4
82	Proven Intra and Interobserver Reliability in the Echographic Assessments of Body Fat Changes Related to HIV Associated Adipose Redistribution Syndrome (HARS). <i>Current HIV Research</i> , 2008, 6, 276-278.	0.2	3
83	Severe Hyperbilirubinemia in an HIV-HCV "Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 285-287.	1.0	3
84	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1287-1288.	3.1	3
85	Pregnancy-Related Changes of Antiretroviral Pharmacokinetics: An Argument for Therapeutic Drug Monitoring. <i>Antiviral Therapy</i> , 2017, 22, 361-363.	0.6	3
86	Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 365-367.	0.8	3
87	The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 789-790.	0.8	3
88	No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1467-1468.	0.8	3
89	Different effects of glucocorticoids on darunavir plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 733-735.	0.8	3
90	Association of HIV Infection with Epilepsy and Other Comorbid Conditions. <i>AIDS and Behavior</i> , 2020, 24, 1051-1055.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. <i>International Journal of STD and AIDS</i> , 2020, 31, 1008-1010.	0.5	3
92	Ritonavir/Cobicistat-Induced Cushing Syndrome in HIV Patients Treated With Non-Oral Corticosteroids: A Call for Action?. <i>American Journal of the Medical Sciences</i> , 2021, 361, 137-139.	0.4	3
93	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. <i>Aids</i> , 2021, 35, 2551-2553.	1.0	3
94	Reply to "Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients". <i>Aids</i> , 2011, 25, 1012-1013.	1.0	2
95	Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 119-125.	1.0	2
96	Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 420-422.	1.0	2
97	Liver Injury After Occasional Energy Drink Use in a Patient Living With HIV and Diabetes. <i>Annals of Pharmacotherapy</i> , 2020, 54, 292-293.	0.9	2
98	The prescribing cascade 3.0: a case for recreational drugs in HIV. <i>Aids</i> , 2020, 34, 1253-1255.	1.0	2
99	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	2
100	A Comparison of Tenofovir Predose Concentrations in Generic Pre-exposure Prophylaxis Formulations: A Short Communication. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 643-647.	1.0	2
101	Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings. <i>Drugs in R and D</i> , 2020, 20, 155-160.	1.1	2
102	Methodological education in response to the quality of COVID-19 publications. <i>Pharmacological Research</i> , 2021, 164, 105381.	3.1	2
103	Liver Injury After Dietary Supplements in Patients Living With HIV: A Call to Action. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 243-244.	2.4	2
104	When the absence of an interaction can become clinically relevant. <i>Aids</i> , 2021, 35, 1327-1328.	1.0	2
105	Preventing COVID-19 in assisted living facilities: An impossible task pending vaccination roll out. <i>Preventive Medicine Reports</i> , 2021, 23, 101471.	0.8	2
106	Doravirine/tenofovir disoproxil fumarate/lamivudine-induced alopecia: A case report. <i>International Journal of STD and AIDS</i> , 2022, , 095646242210962.	0.5	2
107	Fatal septic shock due to <i>Gemella morbillorum</i> in two HIV-positive patients. <i>Clinical Microbiology and Infection</i> , 1996, 2, 65-66.	2.8	1
108	Effect of hepatitis B and C clearance on atazanavir exposure. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1409-1411.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Determinants of bone diseases in tenofovir-treated HIV patients. <i>Aids</i> , 2016, 30, 1686-1687.	1.0	1
110	Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1345-1350.	1.6	1
111	Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 605-606.	0.8	1
112	Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 791-792.	0.8	1
113	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. <i>Aids</i> , 2021, 35, 522-524.	1.0	1
114	Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". <i>Clinical Pharmacokinetics</i> , 2021, 60, 829-831.	1.6	1
115	Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 115-117.	0.3	0
116	Psychoactive drugs and HIV. <i>Aids</i> , 2018, 32, 127-128.	1.0	0
117	<i>Pneumocystis carinii</i> pneumonia after the discontinuation of long-term antiretroviral therapy in an HIV-1-infected pregnant woman. <i>Aids</i> , 2003, 17, 940-941.	1.0	0
118	Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation: US evaluation. <i>New Microbiologica</i> , 2010, 33, 263-5.	0.1	0
119	Genomic Characterization of an ST1153 PVL-producing Methicillin Resistant <i>Staphylococcus aureus</i> Clinical Isolate in Italy. <i>New Microbiologica</i> , 2019, 42, 129-131.	0.1	0